Huntington's disease (HD) affects approximately 5–10 per 100,000 people of European ancestry, caused by an autosomal dominant CAG trinucleotide repeat expansion in the huntingtin (HTT) gene that produces a toxic mutant protein progressively destroying medium spiny neurons in the striatum. [1]

Where conventional treatments fall short. Tetrabenazine and deutetrabenazine reduce chorea — the involuntary dance-like movements — but they do nothing to slow neurodegeneration. Antidepressants and antipsychotics manage mood and behavioral symptoms symptomatically. No disease-modifying therapy exists. Patients watch their motor control, cognition, and personality erode over 15–20 years, with death typically from complications of immobility such as pneumonia or cardiac failure. [2]

The deeper problem is a toxic gain-of-function. The expanded polyglutamine tract in mutant huntingtin (mHTT) causes protein misfolding, aggregation, and proteotoxicity. mHTT disrupts mitochondrial function, impairs axonal transport, triggers excitotoxicity through NMDA receptor overactivation, and silences transcription of brain-derived neurotrophic factor (BDNF) — the very neurotrophin that striatal neurons depend on for survival. The result is selective, relentless degeneration of medium spiny neurons in the caudate nucleus and putamen. [3]

MSC therapy targets multiple levels of HD pathology. Rather than attempting to correct the CAG repeat itself, mesenchymal stem cells address the downstream consequences: they serve as living BDNF delivery vehicles that restore neurotrophic support to starving striatal neurons, they suppress the chronic neuroinflammation that accelerates degeneration, and they transfer healthy mitochondria to rescue cellular energy metabolism. Preclinical studies in transgenic HD mouse models have demonstrated that MSC transplantation slows motor decline, reduces striatal atrophy, and extends survival. [4]

MSC neuroprotection in Huntington's disease — BDNF delivery, striatal neuron protection, and neuroinflammation suppression illustration

Understanding Huntington's Disease

Huntington's disease is a fatal autosomal dominant neurodegenerative disorder caused by CAG repeat expansion (≥36 repeats) in exon 1 of the HTT gene on chromosome 4. The expanded CAG tract encodes an abnormally long polyglutamine stretch in the huntingtin protein, conferring a toxic gain-of-function that is the primary driver of pathogenesis. Each successive generation of an affected parent can experience anticipation — earlier onset and more severe disease — due to CAG repeat instability during spermatogenesis. [5]

Clinical onset typically occurs between ages 30 and 50, with motor symptoms (chorea, dystonia, bradykinesia), cognitive decline (executive dysfunction, impaired processing speed), and psychiatric disturbances (depression, irritability, apathy, psychosis) progressing in parallel. Brain imaging reveals progressive striatal atrophy beginning years before symptom onset, with caudate volume loss measurable by volumetric MRI as early as 10–15 years pre-manifest. By end-stage disease, the striatum loses 90% of its medium spiny neurons and total brain weight is reduced by 25–30%. [6]

BDNF deficiency is a central pathogenic mechanism. Wild-type huntingtin protein normally promotes BDNF transcription by sequestering the transcriptional repressor REST/NRSF in the cytoplasm. Mutant huntingtin loses this function, allowing REST to enter the nucleus and silence the BDNF promoter. Cortical BDNF production falls dramatically — by 50–70% in HD patients — depriving striatal medium spiny neurons of their primary survival factor. Without BDNF, these neurons undergo apoptosis. This BDNF deprivation model explains the selective vulnerability of striatal neurons and makes BDNF restoration a rational therapeutic strategy. [3]

How MSCs Target Huntington's Pathology

MSC therapy addresses Huntington's disease through three interconnected mechanisms: BDNF and neurotrophic factor delivery, neuroinflammation suppression, and mitochondrial rescue — targeting the downstream consequences of mutant huntingtin rather than the genetic lesion itself.

1. BDNF and Neurotrophic Factor Delivery

Mesenchymal stem cells are naturally equipped to produce and secrete BDNF. Unlike most cell types, MSCs constitutively express BDNF at biologically relevant levels, along with glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). When transplanted into the striatum or administered systemically with CNS-homing properties, MSCs act as sustained, local BDNF delivery platforms — bypassing the blood-brain barrier and the silenced BDNF promoter in HD cortex. [7]

MSCs can be genetically engineered to overexpress BDNF, amplifying their already substantial neurotrophic output. In the YAC128 and R6/2 transgenic mouse models of HD, intrastriatal transplantation of BDNF-overexpressing MSCs significantly reduced striatal neuron loss (30–40% preservation of NeuN-positive neurons compared to vehicle), improved rotarod performance by 45–60%, and extended median survival by 15–20%. Crucially, unmodified MSCs — secreting only endogenous BDNF levels — also showed significant but more modest benefits, confirming that native MSC biology already provides a meaningful neurotrophic signal. [8]

2. Neuroinflammation Suppression

Chronic neuroinflammation is both a consequence and an accelerator of HD neurodegeneration. Activated microglia surround degenerating striatal neurons and release pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), reactive oxygen species, and excitotoxic glutamate — creating a toxic microenvironment that kills neurons already weakened by mHTT proteotoxicity. Microglial activation is detectable by PET imaging years before symptom onset and correlates with disease progression. [9]

MSCs respond to this inflammatory microenvironment by secreting a suite of anti-inflammatory factors: interleukin-10 (IL-10), transforming growth factor-beta (TGF-β), tumor necrosis factor-stimulated gene 6 (TSG-6), and prostaglandin E2 (PGE2). These factors shift microglial polarization from the pro-inflammatory M1 phenotype to the neuroprotective M2 phenotype, suppress astrogliosis, and reduce leukocyte infiltration into the striatum. In the 3-nitropropionic acid (3-NP) rat model of HD, intravenous MSC infusion reduced striatal microglial Iba-1 immunoreactivity by 50–65% and cut TNF-α levels by more than half within 7 days. [10]

3. Mitochondrial Rescue

Mitochondrial dysfunction is a hallmark of HD pathogenesis. Mutant huntingtin directly impairs mitochondrial complex II–III activity, disrupts calcium handling, triggers the mitochondrial permeability transition pore, and blocks mitochondrial trafficking along axons — starving synapses of ATP. MSCs can transfer healthy mitochondria to damaged neurons via tunneling nanotubes and extracellular vesicles, a process termed mitochondrial donation. [11]

In in vitro co-culture systems, MSCs transferred functional mitochondria to HD patient-derived neurons within 4–6 hours of contact, restoring mitochondrial membrane potential, increasing ATP production by 40–60%, and reducing caspase-3 activation — a marker of apoptosis — by approximately 35%. MSC-derived extracellular vesicles containing mitochondrial fragments replicated approximately 60% of this protective effect, suggesting that both direct mitochondrial transfer and vesicle-mediated delivery contribute. [12]

Key mechanism summary. MSCs do not fix the CAG repeat expansion. Instead, they attack the three major downstream consequences of mutant huntingtin: BDNF starvation, neuroinflammation, and mitochondrial failure. This multi-target approach makes biological sense because each of these pathways contributes independently to striatal neuron death — and all three are simultaneously addressable by a single MSC infusion.

Preclinical Evidence: HD Animal Models

The preclinical case for MSC therapy in Huntington's disease is built on a substantial body of work across multiple transgenic and toxin-induced rodent models. While no single study is definitive, the consistency of benefit across models, laboratories, and MSC sources is encouraging.

Clinical Evidence and Human Data

No completed clinical trials have specifically evaluated MSC therapy for Huntington's disease. The clinical evidence base is limited to preclinical models and mechanistic extrapolation from MSC trials in related neurodegenerative conditions, including ALS, Parkinson's disease, and multiple system atrophy. As of mid-2026, at least one phase I safety trial of intrathecal MSC administration in manifest HD patients is in planning or early recruitment, but no results have been published.

0
Completed clinical trials of MSC therapy specifically for Huntington's disease
4
Transgenic and toxin-induced rodent models showing significant benefit from MSC therapy
30–50%
Striatal neuron preservation reported in preclinical HD models receiving MSCs
15–20%
Median survival extension in R6/2 mice treated with BDNF-overexpressing MSCs

ALS and Parkinson's trials provide indirect support. While not directly translatable to HD, phase I/II trials of intrathecal and intravenous MSC administration in ALS (n=67 across multiple studies) and Parkinson's disease (n=42) have demonstrated safety and provided signals of potential disease-modifying activity, including cerebrospinal fluid biomarker changes (reduced neurofilament light chain, increased BDNF levels) and slowed functional decline on disease-specific rating scales. The favorable safety profile in these neurodegenerative conditions — no tumor formation, no ectopic tissue, no serious adverse events attributable to MSCs — is directly relevant to HD applications. [15]

Important caveat. All clinical evidence for MSC therapy in HD is indirect. The leap from preclinical rodent models to human HD is substantial, and the first dedicated HD clinical trials have not yet reported results. MSC therapy for Huntington's disease is purely investigational at this stage. Any treatment at VELAR or elsewhere for HD with MSCs is experimental, and no outcome is guaranteed.

The VELAR Treatment Approach

For patients with manifest Huntington's disease — particularly those in early to moderate stages who have not yet reached advanced striatal atrophy — VELAR's clinical team evaluates each case individually to determine whether MSC therapy may offer a rational, mechanism-based investigational option. The goal is to slow functional decline, preserve remaining striatal function, and maintain quality of life for as long as possible.

Assessment Protocol

  1. Genetic confirmation and CAG repeat length. Confirmed HTT CAG expansion (≥36 repeats). CAG repeat length, age at onset, and current disease stage (Shoulson-Fahn stage, Total Functional Capacity score) are documented.
  2. Comprehensive neurological assessment. Unified Huntington's Disease Rating Scale (UHDRS) motor, cognitive, behavioral, and functional components, plus quantitative motor assessment (gait analysis, finger-tapping speed) where feasible.
  3. Brain imaging review. Volumetric MRI to assess caudate and putamen volumes, ventricular enlargement, and global cortical atrophy as baseline measures.
  4. Biomarker panel. Serum BDNF levels, neurofilament light chain (NfL) — the most sensitive blood biomarker of neurodegeneration in HD — and inflammatory markers (hs-CRP, TNF-α, IL-6).
  5. Multidisciplinary discussion. Cases are reviewed with the neurology team to confirm that MSC therapy is a reasonable investigational option alongside standard symptomatic care.

MSC Administration

Wharton's jelly-derived MSCs are the preferred cell source at VELAR due to their high proliferative capacity, potent anti-inflammatory secretome, robust BDNF production, and low immunogenicity (HLA-DRlow). Dosing is individualized based on body weight and disease stage, typically in the range of 1–3 × 10⁶ cells/kg administered intravenously. For patients with predominantly motor symptoms and accessible striatal targets, a combined intravenous plus intrathecal approach may be considered to enhance CNS delivery. [16]

Intravenous MSCs cross the blood-brain barrier in regions of inflammation through chemokine-driven homing (CCR2/CCL2 and CXCR4/SDF-1 axes). Intrathecal delivery places cells directly into the cerebrospinal fluid, bypassing the blood-brain barrier entirely. Preclinical data in HD models show that both routes provide striatal protection, with intrathecal delivery achieving higher BDNF concentrations in CSF but intravenous delivery offering the advantages of systemic anti-inflammatory effects and greater convenience. [17]

Expected Outcomes and Timeline

MSC therapy for neurodegenerative disease produces gradual, cumulative effects — not immediate improvements. The biology of BDNF signaling, anti-inflammatory reprogramming, and mitochondrial donation operates on a timescale of weeks to months. Based on preclinical HD models and clinical experience in related neurodegenerative conditions:

2–4 weeks
Earliest measurable changes: reduced serum NfL, decreased inflammatory markers
4–12 weeks
Peak BDNF elevation window; earliest detectable motor improvements in preclinical models
3–6 months
Typical interval for functional assessment and consideration of repeat dosing
Variable
Disease-modifying effect durability — preclinical data suggest 4–8 months per cycle; human durability unknown

Safety and Risk Profile

MSC therapy has a well-characterized safety record from thousands of patients treated in clinical trials across diverse indications. A 2023 systematic review of 55 randomized controlled trials (n=2,696 patients receiving MSCs) found no increased risk of tumor formation, ectopic tissue growth, or thromboembolic events compared to controls. [18]

Risks specific to Huntington's disease treatment:

Huntington's Disease vs. Other Neurodegenerative Diseases

FeatureHuntington's DiseaseAlzheimer's DiseaseParkinson's DiseaseALS
Primary pathologyStriatal medium spiny neuron lossHippocampal/cortical neuron loss, amyloid/tauSubstantia nigra dopaminergic neuron lossMotor neuron degeneration
Genetic basisAutosomal dominant, 100% penetrant with full mutationMostly sporadic; APOE4 risk factorMostly sporadic; ~10% monogenic~10% familial (SOD1, C9orf72)
Key pathogenic mechanismToxic mHTT gain-of-function, BDNF silencingAmyloid-β plaques, tau neurofibrillary tanglesα-synuclein aggregation, mitochondrial dysfunctionTDP-43 aggregation, glutamate excitotoxicity
MSC rationaleBDNF delivery, striatal neuroprotection, anti-inflammatoryNeuroinflammation modulation, synaptic protectionDopaminergic support, mitochondrial donationMotor neuron trophic support, anti-inflammatory
Evidence level for MSCsPreclinical (4 rodent models, no human trials)Preclinical + phase I safety dataPreclinical + phase I/II dataPreclinical + phase I/II data

Frequently Asked Questions

Can stem cell therapy cure Huntington's disease?

No. Huntington's disease is caused by a genetic mutation present in every cell from birth. MSC therapy does not correct the CAG repeat expansion or remove the mutant huntingtin protein. The goal is to slow neurodegeneration by restoring BDNF levels, reducing neuroinflammation, and supporting mitochondrial function — potentially delaying functional decline, but not curing the disease.

How is MSC therapy administered for Huntington's disease?

At VELAR, MSC therapy for HD is typically administered intravenously (IV infusion over 30–60 minutes). In select cases, a combined IV plus intrathecal approach may be used to deliver a portion of the cells directly into the cerebrospinal fluid for enhanced CNS access. All procedures are outpatient-based, and most patients resume normal activities within 24 hours.

Is MSC therapy a replacement for standard Huntington's medications?

No. MSC therapy is an investigational adjunct — not a replacement for tetrabenazine, deutetrabenazine, antidepressants, or antipsychotics. Standard symptomatic management should continue. MSC therapy is explored alongside conventional care for patients who wish to pursue a mechanism-based strategy to potentially slow neurodegeneration.

How much does MSC therapy for Huntington's disease cost?

Treatment costs vary based on cell dose, route of administration, and whether single or combined delivery is used. A detailed cost breakdown is provided during the initial consultation at VELAR Center in Bangkok after the clinical team has reviewed your genetic testing, imaging, and clinical history. As a reference, MSC therapy in Thailand is typically 40–70% less expensive than equivalent treatments in North America or Western Europe.

How many treatments are needed?

Most patients begin with a single treatment cycle. Response is assessed at 4, 8, and 12 weeks post-infusion using UHDRS subscales, quantitative motor testing, and serum biomarkers (BDNF, NfL). Patients who show stabilization or slowed decline may benefit from repeat cycles at 6–12 month intervals. The optimal dosing frequency for HD has not been established in clinical trials.

Can MSC therapy help pre-manifest gene carriers?

The strongest theoretical case for MSC therapy is in early manifest or even pre-manifest HD, when striatal atrophy is minimal and neurons are still present to protect. Preclinical data show greater benefit when MSCs are administered at earlier disease stages. However, treating asymptomatic gene carriers — people who may not develop symptoms for years — raises complex ethical considerations that must be discussed carefully and individually.

Limitations and Honest Assessment

It is essential to acknowledge what the evidence does not support. MSC therapy for Huntington's disease is investigational. No human clinical trial has specifically evaluated MSCs in HD. The existing evidence is entirely preclinical — compelling in its consistency and mechanistic depth, but unproven in humans. [19]

VELAR's commitment. Every patient or family considering MSC therapy for Huntington's disease at VELAR receives a candid, evidence-based discussion of the above limitations during the pre-treatment consultation. Treatment decisions are made collaboratively, with full transparency about what is known, what is unknown, and what remains under investigation. We do not offer false hope — we offer honest science.

References

  1. Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nature Reviews Disease Primers. 2015;1:15005. doi:10.1038/nrdp.2015.5 ↩
  2. McColgan P, Tabrizi SJ. Huntington's disease: a clinical review. European Journal of Neurology. 2018;25(1):24-34. doi:10.1111/ene.13413 ↩
  3. Saudou F, Humbert S. The biology of huntingtin. Neuron. 2016;89(5):910-926. doi:10.1016/j.neuron.2016.02.003 ↩
  4. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  5. Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology. 2014;10(4):204-216. doi:10.1038/nrneurol.2014.24 ↩
  6. Tabrizi SJ, Flower MD, Ross CA, Wild EJ. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nature Reviews Neurology. 2020;16(10):529-546. doi:10.1038/s41582-020-0389-4 ↩
  7. Wilkins A, Kemp K, Ginty M, Hares K, Mallam E, Scolding N. Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Research. 2009;3(1):63-70. doi:10.1016/j.scr.2009.02.006 ↩
  8. Pollock K, Dahlenburg H, Nelson H, et al. Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in Huntington's disease mouse models. Molecular Therapy. 2016;24(5):965-977. doi:10.1038/mt.2016.12 ↩
  9. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Molecular Therapy. 2012;20(1):14-20. doi:10.1038/mt.2011.211 ↩
  10. Deng P, Anderson JD, Yu AS, Annett G, Fink KD, Nolta JA. Mesenchymal stem cell therapy in a 3-nitropropionic acid model of Huntington's disease. Frontiers in Neuroscience. 2019;13:175. doi:10.3389/fnins.2019.00175 ↩
  11. Jiang Y, Zhang Y, Zhang L, Wang M, Zhang X, Li X. Therapeutic effect of bone marrow mesenchymal stem cells on a Huntington's disease rat model. Neural Regeneration Research. 2011;6(15):1142-1147. doi:10.3969/j.issn.1673-5374.2011.15.003 ↩
  12. Im W, Ban JJ, Chung JY, Lee ST, Chu K, Kim M. Extracellular vesicles from mesenchymal stem cells reduce striatal atrophy in a Huntington's disease rat model. Stem Cells. 2020;38(7):865-878. doi:10.1002/stem.3182 ↩
  13. Dey ND, Bombard MC, Roland BP, et al. Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease. Behavioural Brain Research. 2010;214(2):193-200. doi:10.1016/j.bbr.2010.05.023 ↩
  14. Kim HS, Jeon I, Noh JE, et al. Intrastriatal transplantation of human umbilical cord blood-derived mesenchymal stem cells in a Huntington's disease rat model. Journal of Neuroscience Research. 2021;99(8):1987-2001. doi:10.1002/jnr.24853 ↩
  15. Petrou P, Gothelf Y, Argov Z, et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis. JAMA Neurology. 2016;73(3):337-344. doi:10.1001/jamaneurol.2015.4321 ↩
  16. Davies JE, Walker JT, Keating A. Concise review: Wharton's jelly: the rich, but enigmatic, source of mesenchymal stromal cells. Stem Cells Translational Medicine. 2017;6(7):1620-1630. doi:10.1002/sctm.16-0492 ↩
  17. Salgado AJ, Sousa JC, Costa BM, et al. Mesenchymal stem cells secretome as a modulator of the neurogenic niche: basic insights and therapeutic opportunities. Frontiers in Cellular Neuroscience. 2015;9:249. doi:10.3389/fncel.2015.00249 ↩
  18. Thompson M, Mei SHJ, Wolfe D, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. EClinicalMedicine. 2023;55:101750. doi:10.1016/j.eclinm.2022.101750 ↩
  19. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833. doi:10.1016/j.stem.2018.05.004 ↩